Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)
Akira Inoue(Tohoku University Hospital), T. Nukiwa(Tohoku University), Koichi Hagiwara(Jichi Medical University), Akihiko Gemma(Nippon Medical School), Hiroshi Isobe, Kozo Yoshimori(Japan Anti Tuberculosis Association), Kunihiko Kobayashi(Saitama International Medical Center), Ichiro Kinoshita(Hokkaido University), Toshiyuki Harada(Hokkaido hospital), Shoji Okinaga(Tohoku University), Satoshi Oizumi(Hokkaido University), Yasuko Fujita, Yasuo Saijo(Ho Chi Minh City International University), Shunichi Sugawara(Sendai Kousei Hospital), Satoshi Morita(Kyoto University), Hirohisa Yoshizawa(Niigata University Medical and Dental Hospital), Haruto Hirano(Iwate Prefectural Central Hospital), M. Harada, Makoto Maemondo(Miyagi Prefectural Hospital Organization)
Cited by 555
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
A cross-population atlas of genetic associations for 220 human phenotypes
|Nature Genetics|2021|2.4k